Burroughs Wellcome is reconsidering whether to continue safety evaluations of the anxiolytic, and is holding discussions with FDA. Firm withdrew the drug from the market in March following reports of a high incidence of seizures in a study of bulemic patients. FDA's Psychopharmacologic Drugs Advisory Committee agreed in April that a study proposed by Burroughs Wellcome comparing Wellbutrin (bupropion HCl) to imipramine (Ciba Geigy's Tofranil) would be adequate to assess the safety of Wellbutrin.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.